Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cell Rep Med. 2023 Aug 15;4(8):101158. doi: 10.1016/j.xcrm.2023.101158.
Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B cell lymphoma (rrLBCL) but is associated with toxicities that delay recovery. While the biological mechanisms of cytokine release syndrome and neurotoxicity have been investigated, the pathophysiology is poorly understood for prolonged cytopenia, defined as grade ≥3 cytopenia lasting beyond 30 days after CAR T infusion. We performed single-cell RNA sequencing of bone marrow samples from healthy donors and rrLBCL patients with or without prolonged cytopenia and identified significantly increased frequencies of clonally expanded CX3CR1 cytotoxic T cells, expressing high interferon (IFN)-γ and cytokine signaling gene sets, associated with prolonged cytopenia. In line with this, we found that hematopoietic stem cells from these patients expressed IFN-γ response signatures. IFN-γ deregulates hematopoietic stem cell self-renewal and differentiation and can be targeted with thrombopoietin agonists or IFN-γ-neutralizing antibodies, highlighting a potential mechanism-based approach for the treatment of CAR T-associated prolonged cytopenia.
自体抗 CD19 嵌合抗原受体 T 细胞(CAR T)疗法在复发/难治性大 B 细胞淋巴瘤(rrLBCL)中非常有效,但与延迟恢复相关的毒性。虽然已经研究了细胞因子释放综合征和神经毒性的生物学机制,但对于持续时间超过 30 天的 CAR T 输注后出现的≥3 级血细胞减少症的发病机制仍了解甚少。我们对来自健康供体和伴有或不伴有持续性血细胞减少症的 rrLBCL 患者的骨髓样本进行了单细胞 RNA 测序,并鉴定出与持续性血细胞减少症相关的 CX3CR1 细胞毒性 T 细胞明显增加的克隆扩增频率,这些细胞表达高干扰素(IFN)-γ和细胞因子信号基因集。与此一致,我们发现这些患者的造血干细胞表达 IFN-γ反应特征。IFN-γ失调造血干细胞自我更新和分化,可以用血小板生成素激动剂或 IFN-γ 中和抗体靶向,突出了一种潜在的基于机制的方法来治疗 CAR T 相关的持续性血细胞减少症。